CAMSAP3 depletion induces lung cancer cell senescence-associated phenotypes through extracellular signal-regulated kinase inactivation.
CAMSAP3
cellular senescence-associated phenotypes
cyclin D1
extracellular signal-regulated kinase 1/2 (ERK1/2)
lung cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
10
07
2021
received:
29
05
2021
accepted:
09
10
2021
pubmed:
2
11
2021
medline:
18
3
2022
entrez:
1
11
2021
Statut:
ppublish
Résumé
Cellular senescence is an aging-related process found in cancer cells that contributes to irreversible growth arrest and tumor aggressiveness. Recently, calmodulin-regulated spectrin-associated protein 3 (CAMSAP3), a minus-end microtubule-stabilizing protein, has received increasing attention in cancer cell biology. However, the biological role of CAMSAP3 on senescence in human lung cancer remains incompletely understood. The function of CAMSAP3 on the regulation of cellular senescence-associated phenotypes in human non-small cell lung cancer H460 cells were determined in CAMSAP3 deletion (H460/C3ko) cells. The effects of CAMSAP3 on cell proliferation were investigated using MTT and colony formation assays. The cell cycle activity was evaluated by flow cytometry and the senescence-associated phenotypes were observed by SA-β-Gal staining. Quantitative RT-PCR and westen blot were used to evaluate the expression of cell cycle and senescence markers. Moreover, the interaction of CAMSAP3-ERK1/2 and possible partner protein was quantified using immunoprecipitation/mass spectrometry and immunofluorescence. Lastly, an xenograft model were performed. CAMSAP3 knockout promotes lung cancer cell senescence-associated phenotypes and induces G1 cell cycle arrest. Mechanistic investigation revealed that phosphorylated ERK (p-ERK) was markedly downregulated in CAMSAP3-deleted cells, suppressing cyclin D1 expression levels, and full-length CAMSAP3 abrogated these phenotypes. Proteomic analysis demonstrated that vimentin, an intermediate filament protein, is required as a scaffold for CAMSAP3-modulating ERK signaling. Furthermore, an in vivo tumor xenograft experiment showed that tumor initiation is potentially delayed in CAMSAP3 knockout tumors with the downregulation of p-ERK and cyclin D1, resulting in a senescence-like phenotype. This study is the first to report an intriguing role of CAMSAP3 in lung carcinoma cell senescence-associated phenotypes via the modulation of p-ERK/cyclin D1 signaling.
Sections du résumé
BACKGROUND
Cellular senescence is an aging-related process found in cancer cells that contributes to irreversible growth arrest and tumor aggressiveness. Recently, calmodulin-regulated spectrin-associated protein 3 (CAMSAP3), a minus-end microtubule-stabilizing protein, has received increasing attention in cancer cell biology. However, the biological role of CAMSAP3 on senescence in human lung cancer remains incompletely understood.
METHODS
The function of CAMSAP3 on the regulation of cellular senescence-associated phenotypes in human non-small cell lung cancer H460 cells were determined in CAMSAP3 deletion (H460/C3ko) cells. The effects of CAMSAP3 on cell proliferation were investigated using MTT and colony formation assays. The cell cycle activity was evaluated by flow cytometry and the senescence-associated phenotypes were observed by SA-β-Gal staining. Quantitative RT-PCR and westen blot were used to evaluate the expression of cell cycle and senescence markers. Moreover, the interaction of CAMSAP3-ERK1/2 and possible partner protein was quantified using immunoprecipitation/mass spectrometry and immunofluorescence. Lastly, an xenograft model were performed.
RESULTS
CAMSAP3 knockout promotes lung cancer cell senescence-associated phenotypes and induces G1 cell cycle arrest. Mechanistic investigation revealed that phosphorylated ERK (p-ERK) was markedly downregulated in CAMSAP3-deleted cells, suppressing cyclin D1 expression levels, and full-length CAMSAP3 abrogated these phenotypes. Proteomic analysis demonstrated that vimentin, an intermediate filament protein, is required as a scaffold for CAMSAP3-modulating ERK signaling. Furthermore, an in vivo tumor xenograft experiment showed that tumor initiation is potentially delayed in CAMSAP3 knockout tumors with the downregulation of p-ERK and cyclin D1, resulting in a senescence-like phenotype.
CONCLUSION
This study is the first to report an intriguing role of CAMSAP3 in lung carcinoma cell senescence-associated phenotypes via the modulation of p-ERK/cyclin D1 signaling.
Identifiants
pubmed: 34724356
doi: 10.1002/cam4.4380
pmc: PMC8683528
doi:
Substances chimiques
Amphetamines
0
Camsap3 protein, mouse
0
Microtubule-Associated Proteins
0
fepracet
2792-95-2
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8961-8975Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Res. 2015 Jun 1;75(11):2349-62
pubmed: 25855378
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Cancer Med. 2015 May;4(5):745-58
pubmed: 25684390
Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9750-9755
pubmed: 30190432
Drug Resist Updat. 2012 Feb-Apr;15(1-2):123-31
pubmed: 22365330
Lung Cancer. 2011 Jan;71(1):3-10
pubmed: 20951465
Cell Cycle. 2012 Jun 15;11(12):2285-302
pubmed: 22684298
Cancer Res. 2014 Jan 15;74(2):412-9
pubmed: 24408923
Cancer Discov. 2017 Feb;7(2):165-176
pubmed: 27979832
Sci Rep. 2018 May 22;8(1):8009
pubmed: 29789636
J Recept Signal Transduct Res. 2015;35(6):600-4
pubmed: 26096166
Nat Rev Mol Cell Biol. 2014 Jul;15(7):482-96
pubmed: 24954210
Exp Mol Med. 2020 Jan;52(1):130-151
pubmed: 31959867
Int J Cancer. 2012 Apr 15;130(8):1715-25
pubmed: 22025288
Cell Death Discov. 2017 Aug 21;3:17049
pubmed: 28845296
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
Nat Rev Cancer. 2008 Jul;8(7):512-22
pubmed: 18574463
Trends Cell Biol. 2015 Nov;25(11):651-665
pubmed: 26437588
EMBO Rep. 2005 Feb;6(2):158-64
pubmed: 15678155
Mol Neurobiol. 2018 Feb;55(2):1259-1270
pubmed: 28116547
Cancer Cell. 2016 Jan 11;29(1):75-89
pubmed: 26725216
Carcinogenesis. 2012 Jun;33(6):1178-86
pubmed: 22467239
Nat Rev Cancer. 2003 May;3(5):339-49
pubmed: 12724732
Cell. 2005 Feb 25;120(4):513-22
pubmed: 15734683
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Histochem Cell Biol. 2005 Mar;123(3):263-73
pubmed: 15742196
Tumour Biol. 2015 Aug;36(8):5987-97
pubmed: 25731732
Cell Mol Life Sci. 2019 Mar;76(6):1169-1183
pubmed: 30599068
Neoplasia. 2013 Jul;15(7):727-37
pubmed: 23814485
Int J Clin Pract. 2004 Dec;58(12):1134-41
pubmed: 15646411
Oxid Med Cell Longev. 2018 Jan 31;2018:3537471
pubmed: 29636841
FEBS Lett. 2017 Aug;591(16):2379-2393
pubmed: 28726242
J Cell Sci. 2018 Oct 29;131(21):
pubmed: 30282632
Oncogene. 2012 Jul 5;31(27):3287-97
pubmed: 22020331
Cancer Metastasis Rev. 2016 Mar;35(1):75-91
pubmed: 27018053
Nat Commun. 2017 May 10;8:15208
pubmed: 28489070
Cell Death Differ. 2013 Sep;20(9):1241-9
pubmed: 23852369
J Mol Biol. 2019 Jul 12;431(15):2629-2643
pubmed: 31153901
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20029-34
pubmed: 23169647
Cell Death Dis. 2017 Apr 6;8(4):e2739
pubmed: 28383561
Nat Cell Biol. 2019 Jan;21(1):94-101
pubmed: 30602768
FASEB J. 2014 Jul;28(7):2879-90
pubmed: 24652946
Cancer Med. 2021 Dec;10(24):8961-8975
pubmed: 34724356
Cancer Res. 2009 Mar 1;69(5):1748-57
pubmed: 19223555
Am J Physiol Gastrointest Liver Physiol. 2004 May;286(5):G736-46
pubmed: 14701721
Aging (Albany NY). 2017 Nov 14;9(11):2352-2375
pubmed: 29140794